- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02884960
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
Safety and Efficacy of Embozene® Microspheres for Uterine Fibroid Embolization Compared to Embosphere® Microspheres for Symptomatic Relief From Uterine Fibroids
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The uterine fibroid embolization (UFE) procedure is an accepted, minimally invasive treatment option for patients with symptomatic uterine fibroids. Studies evaluating the outcomes after this procedure have established that the use of polyvinyl alcohol particles and Embosphere Microspheres is associated with best clinical and imaging outcomes. Embozene Microspheres represent a new embolic agent that is being evaluated for use for the treatment of symptomatic fibroids. The purpose of this study is to evaluate the safety and effectiveness of Embozene Microspheres compared with Embosphere Microspheres for the treatment of symptomatic uterine fibroids.
A total of 118 patents with symptomatic uterine fibroids will be enrolled at 6 sites. A questionnaire designed to assess symptom severity and health-related quality of life in patients will be administered to patients at the time of enrollment. In addition, a contrast-enhanced magnetic resonance imaging (MRI) examination will be performed to confirm the diagnosis of fibroids. Patients will then undergo the uterine fibroid embolization procedure. The embolic agent used for the procedure (Embosphere Microspheres or Embozene Microspheres) will be randomly assigned. Patients will be seen 1 month, 3 months, and 6 months and contacted 12 months after the procedure so that the same questionnaire can be used to assess clinical outcomes. In addition, an MRI will be performed 3 months after the procedure to determine the imaging response to treatment.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Barbara MacDowell
- Phone Number: 518-262-5149
- Email: macdowb@mail.amc.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- She is able to provide informed consent and sign the Institutional Review Board approved informed consent form.
- She is pre-menopausal and 30-50 years of age at the time of enrollment.
- She is not actively attempting to become pregnant for a minimum of 1 year after UFE, or practicing abstinence and willing to continue for a minimum of 1 year after UFE, or is surgically sterile.
- She is suffering from clinically significant symptoms attributed to the presence of uterine fibroids including abnormal menstrual bleeding and/or bulk-related symptoms including pelvic pain/discomfort, abdominal distension, urinary symptoms (including but not limited to increased urinary frequency or urinary hesitancy), and/or dyspareunia.
Exclusion Criteria:
- She has a history of pelvic malignancy.
- She is pregnant or intends to become pregnant within 12 months of the planned UFE procedure.
- She has had an abnormal PAP smear (anything other than normal or ASCUS - Atypical Squamous Cells of Unknown Significance) within 12 months of the planned UFE procedure.
- She has a coexisting condition that might explain the presenting symptoms (including but not limited to adenomyosis, endometrial hyperplasia, endometriosis, and complex ovarian cysts).
- She has evidence of current or recent pelvic inflammatory disease or uterine infection.
- She has another serious medical condition that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, chronic obstructive pulmonary disease, myocardial infarction, congestive heart failure, etc.)
- She has a severe contrast allergy or renal insufficiency that would represent a contraindication to the administration of iodine-based or gadolinium-based contrast agents.
- She has a contraindication to magnetic resonance imaging (MRI).
- She has one or more MRI findings including a uterine size >20 cm in greatest length, a dominant fibroid with a greatest diameter >12 cm, an intracavitary submucosal fibroid, or non enhancing dominant fibroids.
- In the judgment of the investigator, she is unable or unlikely to be able to comply with the study procedures and requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Embozene Microspheres
Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
|
This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels.
This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die.
This in turn can lead to the relief of symptoms associated with fibroids.
|
Active Comparator: Embosphere Microspheres
Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
|
This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels.
This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die.
This in turn can lead to the relief of symptoms associated with fibroids.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fibroid Infarction Rate
Time Frame: 3 Months
|
The primary effectiveness endpoint for this study is the proportion of patients with a global rate of infarction for all fibroids present within the uterus that is >90% as seen on contrast-enhanced MRI.
|
3 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptom Severity
Time Frame: 12 Months
|
The percentage of patients experiencing improvement in symptom severity after the uterine fibroid embolization procedure.
|
12 Months
|
Health-Related Quality of Life
Time Frame: 12 Months
|
The percentage of patients experiencing improvement in health-related quality of life after the uterine fibroid embolization procedure.
|
12 Months
|
Uterine Volume
Time Frame: 3 Months
|
The change in uterine volume as seen on MRI examinations performed 3 months after the embolization procedure.
|
3 Months
|
Dominant Fibroid Volume
Time Frame: 12 Months
|
The change in dominant fibroid volume as seen on MRI examinations performed 3 months after the embolization procedure.
|
12 Months
|
Frequency of Adverse Events After Treatment
Time Frame: 12 Months
|
The frequency of adverse events occurring after embolization will be monitored and reported.
|
12 Months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gary Siskin, MD, Community Care Physicians
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1166710
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Fibroids
-
IceCure Medical Ltd.Withdrawn
-
The Cleveland ClinicCompletedUterine Fibroids, Menorrhagia, EndometriosisUnited States
-
Trieu, Nguyen Thi, M.D.Completed
-
Elizabeth A. StewartCompletedUterine Fibroids | Myomas | Uterine Leiomyomas | FibroidsUnited States
-
Instituto Valenciano de Infertilidad, IVI VALENCIATerminated
-
Mayo ClinicEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedUterine Fibroids | Myomas | Fibroids | Symptomatic Uterine LeiomyomasUnited States
-
Acessa Health, Inc.Active, not recruiting
-
InSightecTerminatedUterine Fibroids, With Unexplained InfertilityUnited States
-
AbbVieEnrolling by invitation
-
Mirabilis Medica, Inc.CompletedUterine Fibroids (Leiomyomas)Mexico
Clinical Trials on Uterine Fibroid Embolization
-
Worthington-Kirsch, Robert L., M.D.Terumo Medical Corporation; Biocompatibles UK LtdCompletedUterine Neoplasms | Leiomyoma | LeiomyomatosisUnited States
-
U.S. Army Medical Research and Development CommandGeorgetown University; University of Pittsburgh; The Cleveland Clinic; Walter Reed...Unknown
-
Mayo ClinicEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedUterine Fibroids | Myomas | Fibroids | Symptomatic Uterine LeiomyomasUnited States
-
Acessa Health, Inc.Active, not recruiting
-
Odense University HospitalCompletedUterine Fibroids | Arterial EmbolizationDenmark
-
Dartmouth-Hitchcock Medical CenterPatient-Centered Outcomes Research Institute; Mayo Clinic; Montefiore Medical... and other collaboratorsCompletedUterine FibroidUnited States
-
Boston Scientific CorporationCompletedUterine Neoplasms | Leiomyoma | Leiomyomatosis | Uterine Fibroids | MenorrhagiaUnited States
-
Ariel UniversityCompletedLaser Hysteroscopic Ablation of Submucous MyomaSpain, Italy, Israel
-
Philips HealthcareCompleted